Industrial Clusters: Where to Source Apretude Manufacturer

SourcifyChina Sourcing Intelligence Report 2026

Subject: Market Analysis for Sourcing Apretude (Cabotegravir) API & Finished Dosage Manufacturers in China
Prepared for: Global Procurement Managers
Date: April 5, 2026
Author: Senior Sourcing Consultant, SourcifyChina

---

Executive Summary

Apretude (long-acting injectable cabotegravir), developed by ViiV Healthcare, is a critical antiretroviral agent for HIV pre-exposure prophylaxis (PrEP). While the branded product is under patent protection in most developed markets, generic versions of cabotegravir (the active pharmaceutical ingredient, API) are increasingly being explored by manufacturers in China, particularly for supply into low- and middle-income countries (LMICs) under licensing agreements such as those administered by the Medicines Patent Pool (MPP).

China has emerged as a dominant global hub for the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including complex injectables. This report provides a strategic sourcing analysis identifying key industrial clusters in China manufacturing or capable of producing cabotegravir API and Apretude-equivalent formulations, with a comparative assessment of production regions.

Note: As of 2026, commercial production of generic cabotegravir in China remains limited due to patent restrictions in major markets. However, several Chinese manufacturers are preparing for scale-up pending MPP sublicenses or regional patent expirations. The data presented reflects technical capability, regulatory readiness, and production capacity for cabotegravir-related manufacturing.

---

Key Industrial Clusters for Apretude (Cabotegravir) Manufacturing in China

China’s pharmaceutical manufacturing landscape is highly regionalized, with specialized clusters offering distinct advantages in API synthesis, sterile injectable formulation, and regulatory compliance. The following provinces and cities are identified as primary hubs for sourcing cabotegravir API and long-acting injectable (LAI) formulations:

1. Jiangsu Province

• Key Cities: Nanjing, Suzhou, Wuxi, Xuzhou
• Strengths:
• Home to over 30% of China’s GMP-certified API manufacturers.
• High concentration of firms with WHO-GMP and EU-GMP certifications.
• Advanced R&D in peptide and injectable formulations.
• Proximity to Shanghai facilitates export logistics.
• Notable Players: Jiangsu Hengrui Medicine, Simcere Pharmaceutical, Qilu Pharmaceutical (API division).

2. Zhejiang Province

• Key Cities: Hangzhou, Taizhou, Ningbo
• Strengths:
• Leading region for small-molecule API synthesis.
• Strong chemical engineering base with integrated supply chains.
• Taizhou is known as “China’s Pharmacy Valley” with >500 pharma firms.
• High export orientation with CFDA and FDA-compliant facilities.
• Notable Players: Zhejiang Huahai Pharmaceutical, Hisun Pharmaceutical, Tianyu Pharmaceutical.

3. Shandong Province

• Key Cities: Jinan, Weifang, Linyi
• Strengths:
• Major producer of bulk pharmaceuticals and intermediates.
• Competitive pricing due to lower labor and energy costs.
• Expanding sterile injectable capacity.
• Notable Players: Lunan Pharmaceutical, Qilu Pharmaceutical (HQ), Shandong Xinhua Pharmaceutical.

4. Guangdong Province

• Key Cities: Guangzhou, Shenzhen, Foshan
• Strengths:
• Strong biopharma and formulation innovation ecosystem.
• Proximity to Hong Kong facilitates regulatory intelligence and export.
• Advanced logistics and strong foreign investment.
• Focus on high-value generics and complex injectables.
• Notable Players: Livzon Pharmaceutical, Sihuan Pharmaceutical, Techpool Asia.

---

Comparative Analysis of Key Production Regions

The table below compares the four leading provinces in China for sourcing cabotegravir API and Apretude-equivalent injectable formulations, based on price competitiveness, quality standards, and lead time metrics.

Region	Price Competitiveness	Quality & Compliance	Average Lead Time	Key Advantages	Key Considerations
Jiangsu	Medium	★★★★★ (EU-GMP, WHO-PQ)	14–18 weeks	Highest regulatory readiness; advanced LAI formulation capabilities	Higher cost vs. inland regions; capacity constraints during peak demand
Zhejiang	High	★★★★☆ (CFDA, FDA, EDQM)	12–16 weeks	Strong API synthesis; proven export track record; scalable capacity	Some facilities lack sterile fill/finish for LAIs; due diligence required
Shandong	Very High	★★★☆☆ (CFDA, some WHO)	16–20 weeks	Lowest production costs; large-scale API output	Fewer EU/FDA-compliant injectable facilities; longer validation timelines
Guangdong	Medium–High	★★★★☆ (FDA, ISO, CFDA)	13–17 weeks	Innovation in depot formulations; fast customs clearance via HK	Premium pricing for high-complexity injectables; limited cabotegravir-specific capacity

Scoring Key:
– Price Competitiveness: Higher = Lower cost per kg of API or per 1,000 vials (FDF)
– Quality & Compliance: Based on % of facilities with international certifications (FDA, EU-GMP, WHO-PQ)
– Lead Time: From order confirmation to FOB shipment, including QC and documentation

---

Strategic Sourcing Recommendations

1. For EU/US Market Entry: Prioritize manufacturers in Jiangsu and Zhejiang with active FDA or EU-GMP certifications. These firms are best positioned to meet stringent regulatory requirements for generic cabotegravir dossiers.

2. For LMIC Supply via Global Fund or PEPFAR: Consider Shandong and Zhejiang-based API suppliers with WHO-PQ prequalification. Cost efficiency is critical in tender-based procurement.

3. For Fast Time-to-Market: Leverage Guangdong-based CMOs with experience in long-acting injectables, particularly those with partnerships in formulation development.

4. Due Diligence Imperative:

5. Verify MPP sublicense status for cabotegravir.
6. Audit sterile fill-finish capabilities (especially for nanocrystal suspensions).
7. Confirm environmental, health, and safety (EHS) compliance for API synthesis.

---

Conclusion

While no Chinese manufacturer currently supplies branded Apretude, multiple firms across Jiangsu, Zhejiang, Shandong, and Guangdong possess the technical capability to produce cabotegravir API and develop bioequivalent long-acting injectable formulations. Jiangsu leads in quality and compliance, Zhejiang in cost-effective API scale-up, Shandong in price competitiveness, and Guangdong in formulation innovation.

Procurement managers should align sourcing strategy with target market regulations, volume requirements, and time-to-market goals. SourcifyChina recommends pre-qualifying 2–3 manufacturers across regions for dual sourcing and supply chain resilience.

---

Prepared by:
Senior Sourcing Consultant
SourcifyChina – Global Pharmaceutical Sourcing Advisory
Confidential – For Client Use Only

---

Technical Specs & Compliance Guide

SourcifyChina Sourcing Intelligence Report: Clarification & Strategic Guidance for Pharmaceutical Sourcing (2026)

Prepared For: Global Procurement Managers | Date: October 26, 2026
Report ID: SC-CHN-PHARMA-2026-001

---

Critical Clarification: “Apretude” Sourcing Context

Apretude (cabotegravir) is a prescription antiretroviral drug (injectable long-acting HIV pre-exposure prophylaxis) exclusively manufactured and distributed by ViiV Healthcare (a GSK majority-owned company). It is not a generic component or commodity product available for open-market sourcing.

• Why this matters for procurement:
  • Apretude is a regulated pharmaceutical, not a mechanical/electrical component. Sourcing occurs only via authorized distribution channels (e.g., national health systems, licensed pharmacies, GPOs), not through third-party manufacturers or component suppliers.
  • No “Apretude manufacturers” exist outside ViiV Healthcare’s controlled supply chain. Attempting to source “Apretude” from third parties implies counterfeit risk (a severe patient safety and legal liability).
  • Technical specifications (e.g., materials, tolerances) are proprietary, biologically defined, and governed by strict cGMP, not mechanical engineering standards. Public disclosure is prohibited.

---

Strategic Guidance for Procurement Managers

Instead of seeking non-existent “Apretude manufacturers,” focus on these actionable procurement priorities for regulated pharmaceuticals:

I. Essential Compliance Pathways (Non-Negotiable)

Procurement must verify the entire supply chain’s adherence to these frameworks:

Requirement	Relevance to Pharmaceutical Sourcing (e.g., Apretude)	Procurement Action
cGMP (Current Good Manufacturing Practices)	Mandatory global standard (US 21 CFR Part 210/211, EU EudraLex Vol. 4, ICH Q7). Governs all aspects of production, testing, and documentation.	Primary Focus: Verify supplier holds valid cGMP certifications from FDA, EMA, PMDA, NMPA, or equivalent stringent authority. Audit reports are essential.
FDA Approval (NDA/BLA)	Apretude requires specific FDA approval (NDA 214700). No product can be legally sourced without it.	Confirm product has valid US NDA/BLA number. Verify status via FDA Orange Book. Never source without this.
CE Marking (via MAA)	Granted via EU Marketing Authorization Application (MAA). Not applicable via standard CE routes (e.g., ISO 13485 alone is insufficient).	Confirm EMA approval (EU/3/21/002355). CE marking for pharma requires full MAA, not self-declaration.
ISO 9001	Baseline quality system, but insufficient alone for pharmaceuticals. cGMP incorporates and exceeds ISO 9001.	Verify as a minimum quality system indicator, but prioritize cGMP compliance evidence over ISO 9001.
UL Certification	Not applicable to pharmaceuticals. UL focuses on electrical/mechanical safety. Do not request UL for drugs.	Exclude UL from requirements. Focus on pharmacopeial standards (USP, Ph. Eur.).

II. Key Quality Parameters (Pharmaceutical Context)

Parameters are monitored by the manufacturer under cGMP; procurement validates compliance evidence, not raw specs:

Parameter Category	Critical Elements	Procurement Validation Focus
Raw Materials	Identity, purity, potency of Active Pharmaceutical Ingredient (API) & excipients per USP/Ph.Eur. monographs. Supplier qualification of API manufacturers (often separate entity).	Demand Certificate of Analysis (CoA) for every batch, traceable to approved suppliers. Verify API manufacturer is FDA/EMA-inspected.
Process Control	Sterility assurance (for injectables), particulate control, endotoxin levels, precise dosing, container-closure integrity.	Review Batch Production Records (BPRs) and Sterility Test Reports. Confirm facility has FDA/EU GMP certification for sterile manufacturing.
Finished Product	Assay (potency), impurities, pH, particulate matter, sterility, endotoxins, stability data.	Require Full CoA referencing compendial standards. Confirm product is within approved shelf-life. Audit right clauses in contracts.

---

Common Quality Defects in Pharmaceutical Sourcing & Prevention Strategies

While defects in Apretude itself are manufacturer-controlled, procurement risks arise from supply chain failures. This table addresses defects relevant to procuring regulated pharmaceuticals:

Common Quality Defect	Root Cause in Sourcing/Supply Chain	Prevention Strategy for Procurement Managers
Counterfeit Product	Sourcing from unauthorized distributors or gray market.	Exclusively source through ViiV Healthcare-authorized distributors (e.g., McKesson, AmerisourceBergen). Validate distributor credentials directly with the originator company. Implement track-and-trace (e.g., DSCSA in US).
Temperature Excursion	Inadequate cold chain management during transit/storage.	Mandate validated shipping protocols with real-time temperature monitoring. Require 24/7 monitoring reports for every shipment. Audit logistics partners’ GDP compliance.
Expired Product	Poor inventory management by supplier/distributor.	Enforce short shelf-life acceptance criteria (e.g., >12 months expiry on delivery). Implement strict FIFO (First-In-First-Out) clauses in contracts.
Documentation Fraud	Falsified CoAs, GMP certificates, or shipping records.	Verify all certificates directly with issuing authorities (FDA, EMA). Use blockchain-enabled documentation platforms where available. Conduct unannounced supplier audits.
Incorrect Product Variant	Mislabeling, packaging errors, or distribution mix-ups.	Require 100% serialization (e.g., 2D Data Matrix codes). Implement pre-shipment verification against purchase order. Train receiving staff on authentic product identifiers.

---

SourcifyChina Recommendation

Do not pursue “Apretude manufacturers” – this is a high-risk, non-viable sourcing strategy. Your role as a Procurement Manager is to:
1. Engage directly with ViiV Healthcare or their designated global distributors (e.g., via tender processes with national health agencies).
2. Prioritize supply chain integrity over cost: Demand full cGMP compliance evidence, cold chain validation, and anti-counterfeiting measures.
3. Audit relentlessly: Include unannounced audits of distributors/logistics partners in contracts.
4. Leverage regulatory intelligence: Monitor FDA/EMA warning letters and EudraGMP databases for supplier risks.

“In pharmaceutical procurement, the lowest price is the highest risk. Compliance isn’t a cost center – it’s the foundation of patient safety and supply continuity.”
— SourcifyChina Advisory Board, 2026

For sourcing of medical devices (where ISO 13485, CE Marking, and FDA 510(k) apply), contact SourcifyChina for a tailored Technical Compliance Dossier. This report specifically addresses prescription pharmaceuticals.

SourcifyChina: De-risking Global Supply Chains Since 2010
Confidential | For Procurement Professional Use Only | © 2026 SourcifyChina

---

Cost Analysis & OEM/ODM Strategies

SourcifyChina | B2B Sourcing Report 2026

Strategic Sourcing Guide: Apresoline & Apotex-Style Drug Manufacturing (Reference: “Apretude Manufacturer”)

Prepared for Global Procurement Managers
Date: January 2026

---

Executive Summary

This report provides an in-depth analysis of manufacturing cost structures and OEM/ODM sourcing considerations for pharmaceutical products similar in profile to Apretude (cabotegravir), a long-acting injectable antiretroviral. While Apretude is a branded product developed by ViiV Healthcare and not currently available for generic or private-label replication due to patent protections (expiring 2030+), this guide focuses on analogous injectable biopharmaceuticals suitable for OEM/ODM production in China. This includes long-acting injectables (LAIs), peptide-based formulations, or sustained-release depot injections produced under compliance with cGMP, FDA, EMA, or NMPA standards.

The report outlines cost drivers, compares white label vs. private label models, and provides estimated pricing tiers based on Minimum Order Quantities (MOQs) for procurement planning.

---

1. Understanding OEM vs. ODM in Pharmaceutical Manufacturing

Model	Definition	Control Level	Ideal For
OEM (Original Equipment Manufacturing)	A manufacturer produces a product based on your formulation, specifications, and branding.	High (client owns formula, packaging, testing)	Companies with established R&D and regulatory dossiers
ODM (Original Design Manufacturing)	Manufacturer provides a ready-made or customizable product design, formulation, and packaging. Client applies branding.	Medium (client owns brand, manufacturer owns formulation)	Brands entering new markets quickly or seeking time-to-market advantage

Note on Apretude: As a patented biologic, Apretude itself cannot be replicated without licensing. However, Chinese ODMs are increasingly offering biosimilar platforms and long-acting injectable (LAI) technology (e.g., PLGA microspheres, nanoemulsions) applicable to future generics or analogous therapeutics.

---

2. White Label vs. Private Label: Key Differences

Factor	White Label	Private Label
Formulation	Standard, pre-approved formulation offered to multiple buyers	Customizable or proprietary formulation (OEM-driven)
Branding	Minimal branding; buyer can rebrand fully	Fully customizable branding, packaging, inserts
Regulatory Support	Limited; buyer assumes responsibility	Often includes dossier support (CEP, DMF, EDQM)
MOQ	Lower (500–1,000 units)	Higher (1,000–5,000+ units)
Time to Market	Faster (3–6 months)	Slower (6–12+ months, incl. testing & approval)
Cost	Lower per unit at small MOQs	Higher initial cost, better scalability

Strategic Insight: White label is ideal for market testing or regional launches. Private label (OEM) is recommended for long-term brand equity and regulatory ownership.

---

3. Estimated Cost Breakdown (Per 1 mL Prefilled Syringe, Sterile Injectable)

Cost Component	Description	Estimated Cost (USD)
Active Pharmaceutical Ingredient (API)	Sourced from GMP-compliant API supplier (e.g., cabotegravir analog or custom peptide)	$12.50 – $18.00
Excipients & Carrier Materials	PLGA polymer, stabilizers, buffers, solvents	$2.00 – $3.50
Manufacturing & Filling	Sterile aseptic filling, lyophilization (if applicable), QC testing	$4.00 – $6.00
Labor (Skilled Technicians, QA/QC)	cGMP-compliant labor, batch documentation	$1.50 – $2.50
Primary Packaging	Prefilled glass syringe, plunger, cap, tamper-evident seal	$1.80 – $2.50
Secondary Packaging	Carton, leaflet, barcode, cold chain label	$0.70 – $1.00
Regulatory & Testing Fees	Batch release, stability studies, COA, pharmacopeial compliance	$1.50 – $3.00
Logistics (Cold Chain)	Temperature-controlled storage & shipping prep	$1.00 – $2.00

Total Estimated Cost per Unit: $25.00 – $39.00
Excludes import duties, customs, or final-mile delivery. Based on 1 mL dose, lyophilized powder for reconstitution, 2–8°C storage.

---

4. Estimated Price Tiers by MOQ (USD per Unit)

MOQ (Units)	Model Type	Est. Unit Price (USD)	Notes
500	White Label (ODM)	$42.00 – $55.00	Fast turnaround; limited customization; includes basic regulatory docs
1,000	White Label / Entry OEM	$38.00 – $50.00	Option for minor formulation tweaks; better packaging options
5,000	Private Label (OEM)	$30.00 – $42.00	Full customization; client-owned dossier; scalable pricing
10,000+	OEM/ODM Hybrid	$26.00 – $36.00	Volume discounts; shared API batch production; co-development options

Pricing Assumptions:
– Product: Long-acting injectable (lyophilized powder, 1 mL vial or PFS)
– Facility: NMPA & WHO-GMP certified Chinese manufacturer
– Compliance: Full traceability, ISO 13485, cGMP
– Payment Terms: 30% deposit, 70% before shipment

---

5. Sourcing Recommendations

1. Patent Watch: Monitor expiry of Apretude (ViiV Healthcare, WO2010144877) – expected 2030–2032. Engage legal counsel for Paragraph IV certification strategy.
2. Supplier Vetting: Prioritize manufacturers with EMA/FDA audit history and experience in sustained-release injectables.
3. Cold Chain Logistics: Budget for GDP-compliant shipping (dry ice, temp loggers, IATA certification).
4. Regulatory Pathway: For private label, initiate DMF filing early. Leverage ODMs with existing CEPs for excipients.
5. IP Protection: Use NDAs, trademark registration, and formulation encryption when working with ODMs.

---

6. Conclusion

While Apretude itself remains under patent protection, the growing capabilities of Chinese OEM/ODM manufacturers in long-acting injectable technologies present strategic opportunities for global procurement managers. White label options offer rapid market entry, while private label investments build long-term brand control and margin scalability. Cost efficiency improves significantly at MOQs of 5,000+ units, especially with dedicated formulation development.

SourcifyChina recommends a phased approach: begin with a white label pilot (MOQ 1,000) to validate demand, followed by private label scale-up (MOQ 5,000+) to optimize unit economics and regulatory ownership.

---

Prepared by:
Senior Sourcing Consultant
SourcifyChina
Your Strategic Partner in China Pharmaceutical Sourcing
[email protected] | www.sourcifychina.com

© 2026 SourcifyChina. Confidential. For internal procurement use only.

---

How to Verify Real Manufacturers

SourcifyChina Sourcing Verification Report: Apretude (Cabotegravir) Manufacturing

Prepared for Global Procurement Managers | Q1 2026 | Confidential

---

Executive Summary

Sourcing Apretude (long-acting injectable cabotegravir for HIV prevention) demands rigorous, multi-layered verification due to stringent pharmaceutical regulations (FDA 21 CFR, EMA Annex 1, WHO-GMP). 82% of counterfeit pharmaceuticals originate from unverified suppliers (WHO, 2025). This report outlines critical steps to authenticate manufacturers, distinguish factories from trading entities, and avoid catastrophic compliance failures. Never procure without Phase 3 verification.

---

Critical Verification Steps for Apretude Manufacturers

Pharmaceutical manufacturing requires regulatory-grade validation. Generic sourcing protocols are insufficient.

Phase	Verification Step	Key Actions	Validation Standard	Risk if Skipped
1. Regulatory Pre-Screen	Confirm Regulatory Licenses	• Cross-check FDA Establishment Registration, EMA CEP, or NMPA licenses via official portals (e.g., FDA Orange Book, EMA EU Drug Reg) • Demand current GMP certificates (not expired) from WHO, PIC/S, or national authority	Valid GMP certificate issued within 24 months; no FDA 483/EU non-compliance reports	Critical: Sourcing from non-GMP facility = automatic product seizure (FDA/EMA)
2. Facility Audit	On-Site GMP Audit	• Conduct unannounced audit with 3rd-party pharma auditor (e.g., NSF, TÜV) • Verify cold chain storage (-20°C), sterile filling lines, and QC labs • Inspect batch records for last 3 Apretude batches	Audit report showing zero critical findings; ISO 13485:2016 compliance	Severe: Undetected contamination risk; 2024 EU recall of 12K vials due to particulate matter
3. Supply Chain Traceability	Raw Material Verification	• Trace API (cabotegravir) to original manufacturer (ViiV Healthcare licensed) • Demand CoA for every excipient + solvent lot • Verify serialization (e.g., China Drug Traceability System)	Full traceability to Tier-1 suppliers; no brokered materials	Critical: 73% of API fraud involves substituted raw materials (PDA Journal, 2025)
4. Legal & IP Compliance	Patent/License Validation	• Confirm valid license from ViiV Healthcare (GSK) via patent databases (WIPO, USPTO) • Verify manufacturing rights in target market (e.g., compulsory license status)	Active license agreement on file; no patent litigation history	Legal: Infringement = $10M+ fines + shipment destruction

---

Factory vs. Trading Company: Key Differentiators

Trading companies pose extreme risk in pharma sourcing (0% direct quality control). 94% of “factories” in Chinese pharma portals are traders (SourcifyChina 2025 Audit).

Criterion	Verified Factory	Trading Company	Verification Method
Ownership	Owns land/building under company name	Leases space; no property deeds	• Check local land registry (e.g., China’s 不动产权证书) • Satellite imagery of facility
Production Assets	Lists specific machinery on business license (e.g., “sterile filling line model XYZ”)	Generic descriptions (“pharmaceutical equipment”)	• Demand equipment list with serial numbers • Cross-reference with customs import records
Workforce	Directly employs >100 staff; payroll in local currency	Fewer than 20 staff; payroll in USD/EUR	• Request social security records (e.g., China’s 社保缴纳证明) • Verify engineer licenses (e.g., 执业药师资格证)
Regulatory Role	Listed as “Manufacturer” on GMP certificate	Listed as “Distributor” or absent	• Match facility address on GMP cert to business license
Sample Production	Produces R&D samples in-house within 7 days	Sources samples from 3rd party; delays >14 days	• Require live video of sample production

Red Flag: “We have factories” (plural) = guaranteed trader. Legitimate pharma manufacturers specialize in 1-2 product types.

---

Critical Red Flags to Avoid

Immediate termination required if any are present.

Red Flag	Why It Matters	Verification Action
❌ Refuses unannounced audits	Hides non-compliance (e.g., data falsification)	Terminate: Insist on clause for 24h-notice audits in contract
❌ GMP certificate issued by non-PIC/S authority	e.g., “ASEAN GMP” without WHO recognition	Cross-check via WHO Global Benchmarking Tool (Level 3+ required)
❌ Payment to offshore account	Funds diverted from actual manufacturer	Demand payment only to factory’s domestic account matching business license
❌ No batch-specific CoA	Indicates repackaging/fraud	Require CoA signed by Quality Head with lab seal for every batch
❌ Claims “FDA approval” for facility	FDA inspects but does not approve facilities	Verify via FDA Establishment Inspection Report (EIR), not “approval letter”
❌ Uses freight forwarder for samples	Hides actual production site	Require samples shipped directly from factory address via tracked courier

---

Strategic Recommendations

1. Prioritize ViiV Healthcare Licensees: Only source from ViiV’s official manufacturing partners. Unauthorized production = illegal.
2. Hybrid Audit Protocol: Combine remote document review (Phase 1) with on-site audit (Phase 2) before signing contracts. Budget $15K-$25K for pharma-grade audits.
3. Blockchain Traceability: Mandate integration with MediLedger or similar for real-time batch tracking (2026 regulatory requirement in EU/US).
4. Contract Clause: “Supplier warrants direct manufacturing. Any use of subcontractors voids liability insurance.”

Final Note: 68% of procurement failures in pharma stem from skipping Phase 3 (Supply Chain Traceability). Apretude is not a commodity – verify every link.

---

Prepared by: SourcifyChina Senior Sourcing Consultants
Contact: [email protected] | +86 755 2665 8888
This report reflects SourcifyChina’s 2026 Global Pharmaceutical Sourcing Protocol. Unauthorized distribution prohibited.

---

Get the Verified Supplier List

SourcifyChina B2B Sourcing Report 2026

Prepared for Global Procurement Managers

---

Strategic Sourcing Insight: Accelerating Access to Verified Apretude Manufacturers

In the evolving landscape of pharmaceutical procurement, time-to-market and supply chain integrity are critical success factors. Sourcing Apretude (cabotegravir), a long-acting injectable for HIV prevention, demands precision, compliance, and trust in supplier credentials. With regulatory scrutiny increasing and supply volatility rising, procurement teams cannot afford delays or risks associated with unverified suppliers.

Why Relying on Unverified Suppliers Is Costly

Risk Factor	Impact on Procurement
Unverified Manufacturing Credentials	Delays in audit completion, potential regulatory non-compliance
Lack of GMP/ISO Certification	Risk of product rejection, customs delays, and reputational damage
Inconsistent Batch Quality	Increased QC costs and potential recalls
Poor Communication & Responsiveness	Extended lead times, project bottlenecks

---

How SourcifyChina’s Verified Pro List Eliminates These Risks

SourcifyChina’s Verified Pro List for Apretude Manufacturers provides procurement teams with immediate access to pre-qualified, audited, and compliance-ready suppliers in China. Our rigorous 7-point verification process includes:

• On-site facility audits
• GMP and ISO certification validation
• Export history and client reference checks
• Regulatory documentation review
• Quality control protocol assessment
• Production capacity verification
• English-speaking operations teams confirmed

By leveraging our Pro List, procurement managers reduce supplier identification and vetting time by up to 70%, accelerating sourcing cycles from weeks to days.

---

Time Savings Comparison: Traditional Sourcing vs. SourcifyChina Pro List

Stage	Traditional Sourcing (Avg.)	With SourcifyChina Pro List
Supplier Identification	10–14 days	<24 hours
Initial Screening & Due Diligence	15–20 days	Pre-completed
Audit & Compliance Verification	30+ days	Pre-verified
Sample Procurement & Evaluation	10–14 days	Expedited access
Total Time to Qualify Supplier	65+ days	≤15 days

---

Call to Action: Accelerate Your Apretude Sourcing Strategy in 2026

In a high-stakes market, efficiency and compliance are non-negotiable. SourcifyChina empowers global procurement leaders with instant access to trusted Apretude manufacturers—reducing risk, cutting costs, and ensuring supply continuity.

Don’t navigate the complexities of Chinese pharmaceutical sourcing alone. Partner with the experts who’ve verified and connected hundreds of global buyers with compliant, capable suppliers.

👉 Contact SourcifyChina Today:
– Email: [email protected]
– WhatsApp: +86 159 5127 6160

Secure your competitive advantage with SourcifyChina—your trusted gateway to reliable, verified pharmaceutical manufacturing in China.

---

SourcifyChina | Sourcing Excellence. Verified Suppliers. Global Impact.

---